Expression of CD59, a complement regulator protein and a second ligand of the CD2 molecule, and CD46 in normal and neoplastic colorectal epithelium
1993

CD59 and CD46 in Colorectal Cancer

Sample size: 111 publication Evidence: moderate

Author Information

Author(s): K. Koretz, S. Briiderlein, C. Henne, P. Moller

Primary Institution: Institute of Pathology, University of Heidelberg

Hypothesis

The expression of CD59 and CD46 in colorectal epithelium may have prognostic implications.

Conclusion

CD59 expression is more common in well-differentiated colorectal tumors, while CD46 is consistently expressed across all tumor types.

Supporting Evidence

  • CD59 was expressed in 42 out of 71 colorectal carcinomas.
  • Well-differentiated tumors more often expressed CD59 compared to poorly differentiated tumors.
  • CD46 was consistently expressed in all colorectal carcinomas.

Takeaway

This study looked at two proteins, CD59 and CD46, in colon cancer. CD59 helps protect cells from being attacked by the immune system, and its presence varies in different types of tumors.

Methodology

The study used immunohistochemistry and flow cytometry to analyze tissue samples from colorectal cancer patients.

Limitations

The study is limited by its retrospective design and the small sample size of certain tumor types.

Participant Demographics

The study included 20 normal mucosa samples, 10 adenomas, 71 carcinomas, and 10 liver metastases.

Statistical Information

P-Value

0.018 for Dukes A/B vs C/D comparison; 0.021 for differentiation grade comparison.

Statistical Significance

p<0.05

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication